Contemporary Seasonal Influenza A (H1N1) Virus Infection Primes for a More Robust Response To Split Inactivated Pandemic Influenza A (H1N1) Virus Vaccination in Ferrets
- 1 December 2010
- journal article
- Published by American Society for Microbiology in Clinical and Vaccine Immunology
- Vol. 17 (12), 1998-2006
- https://doi.org/10.1128/cvi.00247-10
Abstract
Human influenza pandemics occur when influenza viruses to which the population has little or no immunity emerge and acquire the ability to achieve human-to-human transmission. In April 2009, cases of a novel H1N1 influenza virus in children in the southwestern United States were reported. It was retrospectively shown that these cases represented the spread of this virus from an ongoing outbreak in Mexico. The emergence of the pandemic led to a number of national vaccination programs. Surprisingly, early human clinical trial data have shown that a single dose of nonadjuvanted pandemic influenza A (H1N1) 2009 monovalent inactivated vaccine (pMIV) has led to a seroprotective response in a majority of individuals, despite earlier studies showing a lack of cross-reactivity between seasonal and pandemic H1N1 viruses. Here we show that previous exposure to a contemporary seasonal H1N1 influenza virus and to a lesser degree a seasonal influenza virus trivalent inactivated vaccine is able to prime for a higher antibody response after a subsequent dose of pMIV in ferrets. The more protective response was partially dependent on the presence of CD8 + cells. Two doses of pMIV were also able to induce a detectable antibody response that provided protection from subsequent challenge. These data show that previous infection with seasonal H1N1 influenza viruses likely explains the requirement for only a single dose of pMIV in adults and that vaccination campaigns with the current pandemic influenza vaccines should reduce viral burden and disease severity in humans.Keywords
This publication has 24 references indexed in Scilit:
- Cross-Neutralization of 1918 and 2009 Influenza Viruses: Role of Glycans in Viral Evolution and Vaccine DesignScience Translational Medicine, 2010
- Serum cross-reactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine.2009
- Swine influenza A (H1N1) infection in two children--Southern California, March-April 2009.2009
- Cloning, expression and immunoassay detection of ferret IFN-γDevelopmental & Comparative Immunology, 2008
- Screening monoclonal antibodies for cross-reactivity in the ferret model of influenza infectionJournal of Immunological Methods, 2008
- Safety and Immunogenicity of Nonadjuvanted and MF59-Adjuvanted Influenza A/H9N2 Vaccine PreparationsClinical Infectious Diseases, 2006
- Cross‐Protectiveness and Immunogenicity of Influenza A/Duck/Singapore/3/97(H5) Vaccines against Infection with A/Vietnam/1203/04(H5N1) Virus in FerretsThe Journal of Infectious Diseases, 2006
- Immunization with Reverse‐Genetics–Produced H5N1 Influenza Vaccine Protects Ferrets against Homologous and Heterologous ChallengeThe Journal of Infectious Diseases, 2006
- Safety and Immunogenicity of an Inactivated Subvirion Influenza A (H5N1) VaccineNew England Journal of Medicine, 2006
- Recent zoonoses caused by influenza A virusesRevue Scientifique et Technique de l'OIE, 2000